Thrivent Financial for Lutherans grew its holdings in shares of Boston Scientific (NYSE:BSX) by 286.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 215,426 shares of the medical equipment provider’s stock after purchasing an additional 159,749 shares during the period. Thrivent Financial for Lutherans’ holdings in Boston Scientific were worth $5,885,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. LPL Financial LLC lifted its holdings in shares of Boston Scientific by 20.3% during the 4th quarter. LPL Financial LLC now owns 131,649 shares of the medical equipment provider’s stock valued at $3,264,000 after purchasing an additional 22,216 shares during the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its holdings in shares of Boston Scientific by 61.4% during the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 937,527 shares of the medical equipment provider’s stock valued at $23,241,000 after purchasing an additional 356,701 shares during the last quarter. First Personal Financial Services lifted its holdings in shares of Boston Scientific by 42.9% during the 4th quarter. First Personal Financial Services now owns 13,015 shares of the medical equipment provider’s stock valued at $323,000 after purchasing an additional 3,908 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Boston Scientific by 371.6% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 7,149,847 shares of the medical equipment provider’s stock valued at $177,245,000 after purchasing an additional 5,633,721 shares during the last quarter. Finally, HBK Investments L P purchased a new stake in shares of Boston Scientific during the 4th quarter valued at $2,516,000. Hedge funds and other institutional investors own 89.38% of the company’s stock.
In other news, SVP Arthur C. Butcher sold 7,500 shares of the firm’s stock in a transaction dated Thursday, May 10th. The stock was sold at an average price of $30.06, for a total transaction of $225,450.00. Following the sale, the senior vice president now directly owns 12,484 shares in the company, valued at approximately $375,269.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Daniel J. Brennan sold 60,209 shares of the firm’s stock in a transaction dated Monday, March 19th. The shares were sold at an average price of $27.87, for a total value of $1,678,024.83. Following the sale, the chief financial officer now owns 299,644 shares in the company, valued at $8,351,078.28. The disclosure for this sale can be found here. Insiders have sold a total of 180,241 shares of company stock worth $5,169,313 over the last ninety days. 0.73% of the stock is owned by insiders.
Shares of BSX opened at $30.40 on Friday. The stock has a market cap of $42.03 billion, a price-to-earnings ratio of 24.13, a P/E/G ratio of 2.17 and a beta of 0.81. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.59 and a current ratio of 0.82. Boston Scientific has a fifty-two week low of $24.54 and a fifty-two week high of $30.84.
Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 25th. The medical equipment provider reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.01. The company had revenue of $2.38 billion for the quarter, compared to the consensus estimate of $2.34 billion. Boston Scientific had a return on equity of 25.10% and a net margin of 1.21%. The firm’s revenue for the quarter was up 10.1% compared to the same quarter last year. During the same period last year, the firm earned $0.29 EPS. analysts expect that Boston Scientific will post 1.39 EPS for the current year.
BSX has been the topic of several research reports. Royal Bank of Canada reissued a “top pick” rating and issued a $32.00 target price on shares of Boston Scientific in a research report on Monday, March 5th. Needham & Company LLC reissued a “buy” rating and issued a $35.00 target price on shares of Boston Scientific in a research report on Tuesday, March 27th. JPMorgan Chase & Co. upped their target price on Boston Scientific from $31.00 to $32.00 and gave the company an “overweight” rating in a research report on Thursday, April 26th. ValuEngine downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, March 7th. Finally, Zacks Investment Research raised Boston Scientific from a “sell” rating to a “hold” rating in a research report on Tuesday, January 30th. One analyst has rated the stock with a sell rating, three have given a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $32.23.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.